Wanbury Limited — PPTs, 22-11-2025: Investor Presentation

Wanbury had a solid H1FY26! Revenue jumped 10.6% YoY to ₹323.2 Cr, with PAT skyrocketing 216.45% YoY to ₹28.67 Cr. EBITDA hit ₹50.77 Cr (+51.26% YoY), boosting margins to 15.71%. The API segment grew 8.2% YoY, while Formulations surged 17.6% YoY and achieved EBITDA positivity.

Growth strategy focuses on launching new APIs (Anaesthetic in Q4, 4 new molecules annually from FY27) and expanding in key regulated markets. Formulations will shift to specialty/chronic products and grow geographically, targeting sustainable profitability. Cost optimization and debt refinancing are key levers.

Recent wins include a perfect USFDA inspection (zero observations) and ANVISA clearance. Debt was refinanced at a lower rate, and a new iron supplement, C-red, launched. SAP S/4HANA is enhancing operations.

H1FY26 metrics: Revenue ₹323.2 Cr, PAT ₹28.67 Cr, EPS ₹8.70.

Management highlighted strong Q2, fueled by efficiency, improved yields, and lower finance costs. They're committed to sustained growth, capacity boosts, and operational excellence to strengthen Wanbury's global footprint.